Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. Denlinger, C., Sym, S., Bendell, J. C., Alsina, M., Watkins, D., Chao, Y., Cubillo, A., Kunz, P. L., Sun, W., Baeksgaard, L., Chen, L., Horgan, K., Frye, S., Kudia, A. J., McDonagh, C., Czibere, A., Moyo, V. M., Chibaudel, B., Bang, Y. AMER SOC CLINICAL ONCOLOGY. 2014

View details for DOI 10.1200/jco.2014.32.15_suppl.tps4148

View details for Web of Science ID 000358613202097